Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Muse CellsMuse Cells and Ischemia-Reperfusion Lung Injury

Muse Cells: Muse Cells and Ischemia-Reperfusion Lung Injury [Ischemia-reperfusion injury (IRI) is one of the main causes of primary graft dysfunction that accounts for 25% of mortality after lung transplantation. Disruption of blood supply and subsequent reperfusion result in organ damage with activating innate and adaptive immune response, leading to inflammatory insults. The IRI after lung transplantation is primarily manifested by permeability pulmonary edema on the basis of pulmonary vascular endothelial cell injury as seen in acute respiratory distress syndrome (ARDS). Stem cells have potent anti-inflammatory and immunomodulatory properties through local paracrine mechanisms. The application of mesenchymal stem cells (MSCs) for ARDS as well as IRI in various organs, therefore, has been interested and extensively investigated in animal models with promising results. Furthermore, two recent clinical randomized, placebo-controlled pilot studies demonstrated that treatment of ARDS with MSCs appears to be safe and feasible.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Muse CellsMuse Cells and Ischemia-Reperfusion Lung Injury

Loading next page...
 
/lp/springer-journals/muse-cells-muse-cells-and-ischemia-reperfusion-lung-injury-0bqjAudYLs

References (27)

Publisher
Springer Japan
Copyright
© Springer Japan KK, part of Springer Nature 2018. Corrected Publication 2019
ISBN
978-4-431-56845-2
Pages
293 –303
DOI
10.1007/978-4-431-56847-6_16
Publisher site
See Chapter on Publisher Site

Abstract

[Ischemia-reperfusion injury (IRI) is one of the main causes of primary graft dysfunction that accounts for 25% of mortality after lung transplantation. Disruption of blood supply and subsequent reperfusion result in organ damage with activating innate and adaptive immune response, leading to inflammatory insults. The IRI after lung transplantation is primarily manifested by permeability pulmonary edema on the basis of pulmonary vascular endothelial cell injury as seen in acute respiratory distress syndrome (ARDS). Stem cells have potent anti-inflammatory and immunomodulatory properties through local paracrine mechanisms. The application of mesenchymal stem cells (MSCs) for ARDS as well as IRI in various organs, therefore, has been interested and extensively investigated in animal models with promising results. Furthermore, two recent clinical randomized, placebo-controlled pilot studies demonstrated that treatment of ARDS with MSCs appears to be safe and feasible.]

Published: Nov 28, 2018

Keywords: Muse cells; Mesenchymal stem cells; Lung transplantation; Ischemia-reperfusion injury; Acute respiratory distress syndrome; Rats

There are no references for this article.